Trial Profile
A Two-Part, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Subjects Employing the Intravenous Endotoxin-Induced Model of Acute Inflammation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs JNJ 26528398 (Primary)
- Indications Inflammation
- Focus Biomarker; Pharmacodynamics
- Sponsors Janssen Research & Development
- 14 Apr 2014 New trial record